Cosciens Biopharma Corp
WKN: A40J1L / ISIN: CA22112H1010Aeterna Zentaris Inc.
12.05.10 16:17
#1
Heron
Aeterna Zentaris Inc.
http://ih.advfn.com/...d=nmona&article=42780487&symbol=N^AEZS
12.05.10 16:31
#2
Heron
Info: Hompage
http://www.aezsinc.com/en/page.php?p=10
12.05.10 16:35
#3
Heron
Events and Webcast
May 18, 2010
Rodman & Renshaw Annual Global Investment Conference
9:00 a.m. (local time)
Grosvenor House Hotel, London, U.K.
Presentation by Juergen Engel, Ph.D., President and CEO
Webcast
May 13, 2010
10:30 a.m., Eastern Time
Annual and Special Meeting of Shareholders
Le Centre Sheraton Montreal Hotel
Salon Jarry & Joyce
Q1-2010 Results Conference call & Webcast
2:30 p.m., Eastern Time
March 24, 2010
2009 4th quarter and full year financial results
10:00 a.m. Eastern Time
Webcast
Rodman & Renshaw Annual Global Investment Conference
9:00 a.m. (local time)
Grosvenor House Hotel, London, U.K.
Presentation by Juergen Engel, Ph.D., President and CEO
Webcast
May 13, 2010
10:30 a.m., Eastern Time
Annual and Special Meeting of Shareholders
Le Centre Sheraton Montreal Hotel
Salon Jarry & Joyce
Q1-2010 Results Conference call & Webcast
2:30 p.m., Eastern Time
March 24, 2010
2009 4th quarter and full year financial results
10:00 a.m. Eastern Time
Webcast
12.05.10 18:58
#9
Heron
News
Aeterna Zentaris: FDA billigt Investigational New Drug (IND) für Application Targeted Doxorubicin-Konjugat Compound, AEZS-108, bei Blasenkrebs
Pressemitteilung Quelle: AEterna Zentaris, Inc. Am Mittwoch, 12. Mai 2010, 07.30 Uhr MESZ
http://translate.google.de/...ml%3Fx%3D0%26.v%3D2&sl=en&tl=de
Pressemitteilung Quelle: AEterna Zentaris, Inc. Am Mittwoch, 12. Mai 2010, 07.30 Uhr MESZ
http://translate.google.de/...ml%3Fx%3D0%26.v%3D2&sl=en&tl=de
13.05.10 20:21
#10
Heron
First Quartal 2010 Finanz-und Betriebsergebnisse
Pressemitteilung
Quelle: AEterna Zentaris, Inc. Am Donnerstag, 13. Mai 2010, 06.45 Uhr MESZ
http://translate.google.de/...ml%3Fx%3D0%26.v%3D1&sl=en&tl=de
Quelle: AEterna Zentaris, Inc. Am Donnerstag, 13. Mai 2010, 06.45 Uhr MESZ
http://translate.google.de/...ml%3Fx%3D0%26.v%3D1&sl=en&tl=de
13.05.10 20:24
#11
Heron
First Quartal 2010 Finanz-und Betriebsergebnisse
Original-Link
http://biz.yahoo.com/prnews/100513/mo606.html?.v=1
http://biz.yahoo.com/prnews/100513/mo606.html?.v=1
03.06.10 23:55
#12
Heron
News
Aeterna Zentaris to Present at Upcoming Needham Annual Healthcare Conference on June 10, 2010
http://www.aezsinc.com/en/page.php?p=60&q=379
http://www.aezsinc.com/en/page.php?p=60&q=379
13.09.10 02:05
#14
Heron
News
Aeterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference on September 14
http://biz.yahoo.com/prnews/100907/mo486.html?.v=1
http://biz.yahoo.com/prnews/100907/mo486.html?.v=1
18.09.10 00:17
#15
Heron
aus" Seeking Alpha" vom 17.09.
http://translate.google.de/...ntaris-is-worth-double%3Fsource%3Dyahoo
07.10.10 00:36
#16
Heron
News: aus BioMedsReport vom 05.10.2010
http://translate.google.de/...ce%3Dtwitterfeed%26utm_medium%3Dtwitter
17.11.10 18:09
#17
iBroker
News 16.-17.11.2011
Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany
Wednesday November 17, 2010, 6:15 am EST
Quelle: http://finance.yahoo.com/news/...ts-prnews-72630191.html?x=0&.v=1
Soon-To-Be-Released Data Poised to Propel AEterna Zentaris Value
November 16, 2010
Quelle: http://seekingalpha.com/article/...eterna-zentaris-value?source=yahoo
Wednesday November 17, 2010, 6:15 am EST
Quelle: http://finance.yahoo.com/news/...ts-prnews-72630191.html?x=0&.v=1
Soon-To-Be-Released Data Poised to Propel AEterna Zentaris Value
November 16, 2010
Quelle: http://seekingalpha.com/article/...eterna-zentaris-value?source=yahoo
17.11.10 22:00
#18
Heron
News
Aeterna Zentaris stellt ermutigende Präklinische Daten auf zwei neuartige oral wirksame Anti-Krebs-Verbindungen in großen Konferenz in Deutschland
http://translate.google.de/...s-prnews-72630191.html%3Fx%3D0%26.v%3D1
http://translate.google.de/...s-prnews-72630191.html%3Fx%3D0%26.v%3D1
29.11.10 23:41
#19
Heron
Rating buy MLV Capital
http://finance.yahoo.com/q/ud?s=AEZS
17.12.10 18:05
#20
Heron
aus"Seeking Alpha" 17.12.2010
Analysten sagen AEterna Zentaris sollte 200% bis 300% höher bewertet werden
http://translate.google.de/...lued-200-to-300-higher%3Fsource%3Dyahoo
http://translate.google.de/...lued-200-to-300-higher%3Fsource%3Dyahoo
09.03.11 09:17
#23
xnomis
70.000.000 USD Lizenzdeal!
Aeterna Zentaris and Yakult Honsha Sign a Development, Commercialization and Licensing Agreement for Lead Oncology Compound, Per
Aeterna Zentaris, Inc. (MM) (NASDAQ:AEZS)
Intraday Stock Chart
Today : Wednesday 9 March 2011
Aeterna Zentaris Inc. (President & CEO: Juergen Engel, (NASDAQ: AEZS) (TSX: AEZ) and Yakult Honsha Co., Ltd. (President: Sumiya Hori, Tokyo: 2267), today announced the signing of an exclusive development, commercialization and licensing agreement for the development, registration and marketing of perifosine, Aeterna Zentaris' lead anti-cancer compound, for Japan. Perifosine, a novel oral PI3K/Akt inhibitor, is currently in two Phase 3 programs for the treatment of colorectal cancer and multiple myeloma in the United States and Europe.
Under the terms of the agreement, Aeterna Zentaris will receive an initial 6 million Euro (US$ 8.3 M) upfront payment and will be entitled to receive additional up to 44 million Euro (US$ 60.9 M) payments upon achieving certain pre-established milestones including clinical and regulatory events in Japan. Furthermore, Aeterna Zentaris will be supplying perifosine to Yakult Honsha on a cost-plus-basis and be entitled to receive double-digit royalties on future net sales of perifosine in Japan. Yakult Honsha will be responsible for the development, registration and commercialization in Japan.
"We are delighted to have a partner such as Yakult Honsha who has a proven track record in oncology and particularly in colon cancer, one of the main indications being targeted with perifosine. This partnership marks another important milestone in our quest to bring perifosine to market worldwide which could provide cancer patients with a novel treatment option. Furthermore, perifosine could generate significant long-term revenue for Aeterna Zentaris while building value for our shareholders," said Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris, and continued, "We have now out-licensed perifosine rights to Keryx Biopharmaceuticals for North America, to Handok for Korea and to Yakult Honsha for Japan, while Aeterna Zentaris retains all rights for the rest of the world. In order to ensure a worldwide timely development of perifosine, Aeterna Zentaris and all its partners have agreed to free access to all data."
Mr. Shigeyoshi Sakamoto, Head, Pharmaceutical Division / Managing Director, Member of the Board of Yakult Honsha, said, "We are delighted to have added perifosine to our pipeline in oncology which we have positioned as our key therapeutic domain. We look forward to pursuing development and commercialization of perifosine in Japan, by appropriately and efficiently utilizing the data of ongoing Phase 3 trials in the United States and Europe for patients with colorectal cancer and multiple myeloma. This partnership will enable us to further strengthen our initiative in the field of colorectal cancer and to embark on new fields including multiple myeloma."
About Perifosine
Perifosine is a novel, oral anticancer treatment that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. The product works by interfering with membranes of cancer cells thereby inhibiting Akt signaling which then affects cell death, growth, differentiation and survival. Perifosine, in combination with chemotherapeutic agents, is currently being studied for the treatment of colorectal cancer, multiple myeloma and other cancers, and is the most advanced anticancer compound of its class in late-stage development. Perifosine as monotherapy, is being explored in other indications. The US Food & Drug Administration ("FDA") has granted perifosine orphan-drug designation in multiple myeloma and neuroblastoma, and Fast Track designations in both refractory advanced colorectal cancer and multiple myeloma. Additionally, an agreement was reached with the FDA to conduct the Phase 3 trials in both of these indications under a Special Protocol Assessment. Perifosine has also been granted orphan medicinal product designation from the European Medicines Agency ("EMA") in multiple myeloma. Furthermore, perifosine has received positive Scientific Advice from the EMA for both the advanced colorectal cancer and multiple myeloma programs, with ongoing Phase 3 trials for these indications expected to be sufficient for registration in Europe.
About Yakult Honsha Co., Ltd.
Yakult Honsha is a leading Japanese company focused on the development and marketing of pharmaceuticals, foods, beverages, and cosmetics. As for pharmaceutical business, Yakult Honsha has an emerging presence in oncology. For more information on Yakult Honsha, visit: http://www.yakult.co.jp/english/index.html or view the following company profile: http://www.yakult.co.jp/english/pdf/profile2010-2011.pdf
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian, endometrial cancer and multiple myeloma. Aeterna Zentaris' innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing Aeterna Zentaris with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results of Aeterna Zentaris and Yakult Honsha to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Aeterna Zentaris and Yakult Honsha to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult Aeterna Zentaris' quarterly and annual filings with the Canadian and U.S. securities commissions, and Yakult Honsha's quarterly and annual filings with Tokyo Stock Exchange, for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. Aeterna Zentaris and Yakult Honsha do not undertake to update these forward-looking statements, and disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.
Aeterna Zentaris, Inc. (MM) (NASDAQ:AEZS)
Intraday Stock Chart
Today : Wednesday 9 March 2011
Aeterna Zentaris Inc. (President & CEO: Juergen Engel, (NASDAQ: AEZS) (TSX: AEZ) and Yakult Honsha Co., Ltd. (President: Sumiya Hori, Tokyo: 2267), today announced the signing of an exclusive development, commercialization and licensing agreement for the development, registration and marketing of perifosine, Aeterna Zentaris' lead anti-cancer compound, for Japan. Perifosine, a novel oral PI3K/Akt inhibitor, is currently in two Phase 3 programs for the treatment of colorectal cancer and multiple myeloma in the United States and Europe.
Under the terms of the agreement, Aeterna Zentaris will receive an initial 6 million Euro (US$ 8.3 M) upfront payment and will be entitled to receive additional up to 44 million Euro (US$ 60.9 M) payments upon achieving certain pre-established milestones including clinical and regulatory events in Japan. Furthermore, Aeterna Zentaris will be supplying perifosine to Yakult Honsha on a cost-plus-basis and be entitled to receive double-digit royalties on future net sales of perifosine in Japan. Yakult Honsha will be responsible for the development, registration and commercialization in Japan.
"We are delighted to have a partner such as Yakult Honsha who has a proven track record in oncology and particularly in colon cancer, one of the main indications being targeted with perifosine. This partnership marks another important milestone in our quest to bring perifosine to market worldwide which could provide cancer patients with a novel treatment option. Furthermore, perifosine could generate significant long-term revenue for Aeterna Zentaris while building value for our shareholders," said Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris, and continued, "We have now out-licensed perifosine rights to Keryx Biopharmaceuticals for North America, to Handok for Korea and to Yakult Honsha for Japan, while Aeterna Zentaris retains all rights for the rest of the world. In order to ensure a worldwide timely development of perifosine, Aeterna Zentaris and all its partners have agreed to free access to all data."
Mr. Shigeyoshi Sakamoto, Head, Pharmaceutical Division / Managing Director, Member of the Board of Yakult Honsha, said, "We are delighted to have added perifosine to our pipeline in oncology which we have positioned as our key therapeutic domain. We look forward to pursuing development and commercialization of perifosine in Japan, by appropriately and efficiently utilizing the data of ongoing Phase 3 trials in the United States and Europe for patients with colorectal cancer and multiple myeloma. This partnership will enable us to further strengthen our initiative in the field of colorectal cancer and to embark on new fields including multiple myeloma."
About Perifosine
Perifosine is a novel, oral anticancer treatment that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. The product works by interfering with membranes of cancer cells thereby inhibiting Akt signaling which then affects cell death, growth, differentiation and survival. Perifosine, in combination with chemotherapeutic agents, is currently being studied for the treatment of colorectal cancer, multiple myeloma and other cancers, and is the most advanced anticancer compound of its class in late-stage development. Perifosine as monotherapy, is being explored in other indications. The US Food & Drug Administration ("FDA") has granted perifosine orphan-drug designation in multiple myeloma and neuroblastoma, and Fast Track designations in both refractory advanced colorectal cancer and multiple myeloma. Additionally, an agreement was reached with the FDA to conduct the Phase 3 trials in both of these indications under a Special Protocol Assessment. Perifosine has also been granted orphan medicinal product designation from the European Medicines Agency ("EMA") in multiple myeloma. Furthermore, perifosine has received positive Scientific Advice from the EMA for both the advanced colorectal cancer and multiple myeloma programs, with ongoing Phase 3 trials for these indications expected to be sufficient for registration in Europe.
About Yakult Honsha Co., Ltd.
Yakult Honsha is a leading Japanese company focused on the development and marketing of pharmaceuticals, foods, beverages, and cosmetics. As for pharmaceutical business, Yakult Honsha has an emerging presence in oncology. For more information on Yakult Honsha, visit: http://www.yakult.co.jp/english/index.html or view the following company profile: http://www.yakult.co.jp/english/pdf/profile2010-2011.pdf
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian, endometrial cancer and multiple myeloma. Aeterna Zentaris' innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing Aeterna Zentaris with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results of Aeterna Zentaris and Yakult Honsha to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Aeterna Zentaris and Yakult Honsha to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult Aeterna Zentaris' quarterly and annual filings with the Canadian and U.S. securities commissions, and Yakult Honsha's quarterly and annual filings with Tokyo Stock Exchange, for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. Aeterna Zentaris and Yakult Honsha do not undertake to update these forward-looking statements, and disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.